Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204565 | 0.90 | SMN1; SMN2 (0.62) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15632082 | 0.85 | SMN1; SMN2 (0.57) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL165333 | 0.84 | SMN1; SMN2 (0.71) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3977744 | 0.81 | TDP1 (0.56) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16614107 | 0.81 | SMN1; SMN2 (0.58) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL172700 | 0.81 | ALDH1A1 (0.56) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19027912 | 0.81 | RAB9A (0.61) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL503004 | 0.81 | KCNMA1 (0.59) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10069688 | 0.81 | SMN1; SMN2 (0.54) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18393241 | 0.81 | SMN1; SMN2 (0.54) | NPC1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| CN-109071523-B | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-7414048-B2 | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| EP-1119568-B1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | FREYNE EDDY JEAN EDGARD (BE) | 2004-01-29 | — | — | US | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |
| EP-1119568-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021959-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | NPC1 2390/4885KDM4E 2072/4885L3MBTL1 3829/4885 |
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | CBR1, CYP2D6, HSD3B1 | NPC1 571/4885KDM4E 2853/4885L3MBTL1 4719/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | NPC1 2390/4885KDM4E 2072/4885L3MBTL1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.